Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Narcolepsy Therapeutics Market, by Type
1.4.2 North America Narcolepsy Therapeutics Market, by Product
1.4.3 North America Narcolepsy Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Narcolepsy Therapeutics Market by Type
3.1 North America Narcolepsy with Cataplexy Market by Country
3.2 North America Narcolepsy Without Cataplexy Market by Country
3.3 North America Secondary Narcolepsy Market by Country
Chapter 4. North America Narcolepsy Therapeutics Market by Product
4.1 North America Sodium Oxybate Market by Country
4.2 North America Selective Serotonin Reuptake Inhibitor Market by Country
4.3 North America Central Nervous System Stimulants Market by Country
4.4 North America Tricyclic Antidepressants Market by Country
4.5 North America Others Market by Country
Chapter 5. North America Narcolepsy Therapeutics Market by Country
5.1 US Narcolepsy Therapeutics Market
5.1.1 US Narcolepsy Therapeutics Market by Type
5.1.2 US Narcolepsy Therapeutics Market by Product
5.2 Canada Narcolepsy Therapeutics Market
5.2.1 Canada Narcolepsy Therapeutics Market by Type
5.2.2 Canada Narcolepsy Therapeutics Market by Product
5.3 Mexico Narcolepsy Therapeutics Market
5.3.1 Mexico Narcolepsy Therapeutics Market by Type
5.3.2 Mexico Narcolepsy Therapeutics Market by Product
5.4 Rest of North America Narcolepsy Therapeutics Market
5.4.1 Rest of North America Narcolepsy Therapeutics Market by Type
5.4.2 Rest of North America Narcolepsy Therapeutics Market by Product
Chapter 6. Company Profiles
6.1 Jazz Pharmaceuticals plc
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Regional Analysis
6.1.4 Research & Development Expenses
6.1.5 Recent strategies and developments:
6.1.5.1 Partnerships, Collaborations, and Agreements:
6.1.5.2 Approvals and Trials:
6.2 Shionogi & Co., Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Research & Development Expenses
6.3 Teva Pharmaceutical Industries Ltd.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expenses
6.4 Pfizer, Inc. (Arena Pharmaceuticals, Inc.)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional & Segmental Analysis
6.4.4 Research & Development Expense
6.5 Bioprojet
6.5.1 Company Overview
6.5.2 Recent strategies and developments:
6.5.2.1 Partnerships, Collaborations, and Agreements:
6.6 Takeda Pharmaceutical Company Limited
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional Analysis
6.6.4 Research & Development Expense
6.7 Ligand Pharmaceuticals, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Research & Development Expenses
6.8 Graymark Healthcare, Inc.
6.8.1 Company Overview
Unique Offerings 